Bloomberg: Sun plant banned by FDA had same issues faced by Ranbaxy

Save

Sun Pharmaceutical&#39;s $3.2 billion buyout offer for Ranbaxy Laboratories also came with a pledge to clean up the act of India&#39;s largest generic drugmaker, which has had four plants banned by the FDA. But Sun also recently had a plant nixed by the FDA, and <em>Bloomberg</em> learned it was for many of the same issues faced by Ranbaxy.